We believe this site might serve you best:

United States

English Continue

This country code will remain if no action is taken to change it.

Don't see your country?
Promega Corporation

Live-Cell, Real-Time Monitoring of cAMP Kinetics with Promega GloSensor™ Technology

MADISON, WISCONSIN (April 3, 2008)

Promega Corporation announces the launch of a breakthrough cell-based biosensor technology, termed GloSensor™ Technology. The non-lytic, live-cell GloSensor cAMP Assay is the first application of the patent-pending technology, which features a genetically engineered form of firefly luciferase. The benefit to screeners and scientists alike will be more biologically relevant data captured directly from living cells.

cAMP is key signaling molecule for many G-protein coupled receptors. GloSensor cAMP Assay is the first bioluminescent cell-based biosensor for the direct, intracellular kinetic monitoring of cAMP, and ideally suited to HTS and uHTS application. "Early testers of the assay are telling us the ease and performance of the assay are phenomenal," says Neal Cosby, Promega Drug Screening Manager. "The kinetic profiling of cAMP afforded by this new technology will give scientists better insight into the biology of living cells under various treatments, such as agonist and antagonist screening." Because researchers simply combine cells, compounds and GloSensor cAMP Assay Reagent, the technology offers 'zero-step' assay potential.

Collaborator and company-sponsored presentations will be given at SBS 14th Annual Conference & Exhibition (April 6-10, 2008) in St. Louis. Promega scientists who developed the genetically engineered bioluminescent biosensors will be present at SBS to discuss the new technology with interested parties.

How the GloSensor cAMP Assay works. GloSensor cAMP Assay was created by fusion of a cAMP binding domain to the wild-type N- and C-termini of native firefly luciferase. New termini were created elsewhere in the luciferase fusion construct. In the absence of cAMP, the genetically modified luciferase containing the cAMP binding domain is in the inactive state (left side of image). Upon binding to cAMP, conformational changes in the cAMP binding domain likely determine the increased luminescence in the activated state that can be detected both in vitro and in living cells (right side of image). Both forms of luciferase are represented in the presence of luciferase substrate.

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.

For more information about a press release or about Promega in general, contact Promega Corporate Affairs at 1-608-274-4330 or complete this form.

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.

Scientists at Your Service

Scientists at Your Service

We offer a range of services to help you succeed using Promega technologies. From product training to set up of automated systems and development of custom applications—our scientific support goes beyond the basics.

Ask us! We are here to help you.